| Assessment Status | Rapid Review Complete |
| HTA ID | 23030 |
| Drug | Deucravacitinib |
| Brand | Sotyktu® |
| Indication | Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 01/06/2023 |
| Rapid review completed | 27/06/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that deucravacitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
